Pharmacology - 13:01
Novartis receives positive CHMP opinion for Mayzent (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)
Novartis receives positive CHMP opinion for Mayzent (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)
Art - Nov 13
Midlands Art Papers launches special issue on inclusion, disability and access in the arts
Midlands Art Papers launches special issue on inclusion, disability and access in the arts
Pharmacology - Nov 12
New Novartis PREVENT data show Cosentyx delivers early relief in axial spondyloarthritis
New Novartis PREVENT data show Cosentyx delivers early relief in axial spondyloarthritis
Health - Nov 12
Sandoz presents real-world data showing effectiveness of Erelzi (etanercept-szzs) in rheumatic disease treatment
Sandoz presents real-world data showing effectiveness of Erelzi (etanercept-szzs) in rheumatic disease treatment
Life Sciences - Nov 12
Stanford opens ’team science’ complex for brain research and molecular discovery
Stanford opens ’team science’ complex for brain research and molecular discovery
science wire
« BACK
Pharmacology - Health - 08.10.2019
Pharmacology - Health - 08.10.2019
Health - Pharmacology - 07.10.2019
Pharmacology - 07.10.2019
Pharmacology - 07.10.2019 
New capsule can orally deliver drugs that usually have to be injected
Coated pill carries microneedles that deliver insulin and other drugs to the lining of the small intestine.
Pharmacology - Life Sciences - 05.10.2019
Health - Pharmacology - 03.10.2019
Life Sciences - Pharmacology - 03.10.2019 
Bringing neuroscience to bear on addiction policy
Keith Humphreys founded the Stanford Network on Addiction Policy to help bring more science to debates over drug policy.
Health - Pharmacology - 02.10.2019 
Immune cells in the spotlight
How do immune cells behave in the body? What happens during immunotherapy, which is designed to encourage the body's own immune system to attack a disease? To answer these questions, the European Union (EU) brings together leading experts from research and the pharmaceutical industry.
Pharmacology - Health - 02.10.2019
Pharmacology - Health - 01.10.2019
Health - Pharmacology - 01.10.2019
Pharmacology - 30.09.2019
Pharmacology - Health - 30.09.2019
Pharmacology - Health - 30.09.2019
Health - Pharmacology - 30.09.2019
Pharmacology - Health - 30.09.2019
Pharmacology - Health - 30.09.2019
Pharmacology - Health - 30.09.2019
Pharmacology - Health - 29.09.2019
Pharmacology - Health - 28.09.2019
Pharmacology - Health - 27.09.2019
Pharmacology - Health - 27.09.2019
Health - Pharmacology - 26.09.2019
Health - Pharmacology - 26.09.2019
Environment - Pharmacology - 25.09.2019
Life Sciences - Pharmacology - 23.09.2019
Pharmacology - Health - 23.09.2019
Health - Pharmacology - 20.09.2019
Pharmacology - Health - 19.09.2019
Pharmacology - Health - 18.09.2019
Pharmacology - Health - 17.09.2019
Pharmacology - Health - 16.09.2019
Pharmacology - Health - 13.09.2019
Pharmacology - Health - 13.09.2019
Pharmacology - Life Sciences - 13.09.2019
Pharmacology - Health - 13.09.2019
Health - Pharmacology - 12.09.2019
Pharmacology - Life Sciences - 12.09.2019
Pharmacology - Health - 12.09.2019
Pharmacology - Health - 12.09.2019
Pharmacology - Health - 11.09.2019
Pharmacology - Life Sciences - 10.09.2019 
X-ray Experiments Contribute to Studies of a Drug Now Approved to Combat Tuberculosis
The U.S. Food and Drug Administration has approved a new antibiotic that, in combination with two existing antibiotics, can tackle one of the most formidable and deadly treatment-resistant forms of the bacterium that causes tuberculosis .
Pharmacology - Health - 10.09.2019
Pharmacology - Health - 10.09.2019
Health - Pharmacology - 10.09.2019
Pharmacology - Health - 09.09.2019
Pharmacology - Health - 09.09.2019
Pharmacology - Health - 06.09.2019
Pharmacology - Health - 06.09.2019
Pharmacology
Results 51 - 100 of 1505.
Novartis receives FDA approval for Beovu , offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients
In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients
Coated pill carries microneedles that deliver insulin and other drugs to the lining of the small intestine.
AveXis presents updated STRONG data at WMS demonstrating a higher mean increase in Hammersmith Functional Motor Scale-Expanded (HFMSE) scores among older SMA Type 2 patients following one-time intrathecal administration of AVXS-101
Older patients (= 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follo
Older patients (= 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follo
New partnership aims to identify new disease mechanisms and potential targets for treatment of non-alcoholic fatty liver disease
A new partnership between scientists at the University of Birmingham and global healthcare company Novo Nordisk aims to discover new treatments for people suffering from fatty liver disease.
A new partnership between scientists at the University of Birmingham and global healthcare company Novo Nordisk aims to discover new treatments for people suffering from fatty liver disease.
Keith Humphreys founded the Stanford Network on Addiction Policy to help bring more science to debates over drug policy.
How do immune cells behave in the body? What happens during immunotherapy, which is designed to encourage the body's own immune system to attack a disease? To answer these questions, the European Union (EU) brings together leading experts from research and the pharmaceutical industry.
Novartis positive 52-week PREVENT data confirm Cosentyx efficacy in addressing entire axSpA spectrum
Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA) Novartis plans FDA submission for nr-axSpA, having submitted to EMA previously.
Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA) Novartis plans FDA submission for nr-axSpA, having submitted to EMA previously.
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
Multiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercialized Novartis to establish
Multiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercialized Novartis to establish
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer IMvigor130 is the fi
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer IMvigor130 is the fi
Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint PALLADIUM is part of Phase III PLATINUM clinical development program, which ev
Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint PALLADIUM is part of Phase III PLATINUM clinical development program, which ev
Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa
Efficacy of Alecensa (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX study Roche will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next generation sequencing (NGS) to detec
Efficacy of Alecensa (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX study Roche will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next generation sequencing (NGS) to detec
Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint , IRIDIUM is largest study in Phase III PLATINUM clinical development p
Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint , IRIDIUM is largest study in Phase III PLATINUM clinical development p
FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders
Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis These two forms of vascu
Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis These two forms of vascu
Novartis Kisqali delivers consistently superior overall survival - MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs.
In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs.
Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer
New real-world data from the Flatiron database supports clinical benefits of Alecensa (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival Final PFS and updated data from the pivotal Phase III ALEX study reinforces efficacy of Alecensa in first-line ALK-positive non-small cell lung cancer and shows progression free survival of nearly three years Roche will present new data at the Europea
New real-world data from the Flatiron database supports clinical benefits of Alecensa (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival Final PFS and updated data from the pivotal Phase III ALEX study reinforces efficacy of Alecensa in first-line ALK-positive non-small cell lung cancer and shows progression free survival of nearly three years Roche will present new data at the Europea
Roche’s Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer
Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone Data wil
Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone Data wil
Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma
The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapy The combination of Tecentriq and Avastin was shown to reduce the risk of disease worsening or death by 45% compared with Tecentriq monotherapy Data from the Phase Ib cancer immunotherapy combination study will be presented at the European So
The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapy The combination of Tecentriq and Avastin was shown to reduce the risk of disease worsening or death by 45% compared with Tecentriq monotherapy Data from the Phase Ib cancer immunotherapy combination study will be presented at the European So
UCLA to lead $25 million study of opioids in rural America
Scientists from the UCLA Integrated Substance Abuse Programs will lead a $25 million study on in rural America.
Scientists from the UCLA Integrated Substance Abuse Programs will lead a $25 million study on in rural America.
Spotlight on... Dr Jane Kinghorn
This week Jane, Director of the Translational Research Office (TRO), talks about developing solutions to unmet medical needs, and new support for Early Career Researchers.
This week Jane, Director of the Translational Research Office (TRO), talks about developing solutions to unmet medical needs, and new support for Early Career Researchers.
How we are tackling dementia and stigma
A language app to improve diagnosis and peer-support dementia coaching are some of the Sydney projects aiming to tackle the obstacles and stigma surrounding dementia.
A language app to improve diagnosis and peer-support dementia coaching are some of the Sydney projects aiming to tackle the obstacles and stigma surrounding dementia.
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer First results from the BFAST study testing Foundation Medici
First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer First results from the BFAST study testing Foundation Medici
FDA approves cobas Babesia, Roche’s first whole blood test for donor screening
Roche is dedicated to helping save patients' lives by delivering state-of-the-art solutions to aid in the protection of the global blood supply from infectious diseases If undetected, Babesia infecti
Roche is dedicated to helping save patients' lives by delivering state-of-the-art solutions to aid in the protection of the global blood supply from infectious diseases If undetected, Babesia infecti
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age-appropriate major milestone gain Updated results from global STR1
New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age-appropriate major milestone gain Updated results from global STR1
FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis
There are currently no U.S. FDA-approved medicines for lupus nephritis The designation is based on the results of the phase II NOBILITY study that showed Gazyva, in combination with standard of care, helped more people achieve a complete renal response than standard of care alone Full results from the NOBILITY study will be presented at a medical meeting later this year Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Gazyva (obinutuzumab) for adults with lupus nephritis.
There are currently no U.S. FDA-approved medicines for lupus nephritis The designation is based on the results of the phase II NOBILITY study that showed Gazyva, in combination with standard of care, helped more people achieve a complete renal response than standard of care alone Full results from the NOBILITY study will be presented at a medical meeting later this year Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Gazyva (obinutuzumab) for adults with lupus nephritis.
Novartis Cosentyx positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA).
Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA).
Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis
Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS) ; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20 pos
Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS) ; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20 pos
Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis
Post-hoc analysis from a Phase III open-label extension study showed a 42 percent reduction in the risk of PPMS patients needing a wheelchair after 6.5 years of OCREVUS treatment compared with patients who started OCREVUS after the double-blind period Interim analysis of Phase IIIb study shows 87 percent of patients with suboptimal response to previous treatment had no evidence of disease activity one year after switching to OCREVUS Separ
Post-hoc analysis from a Phase III open-label extension study showed a 42 percent reduction in the risk of PPMS patients needing a wheelchair after 6.5 years of OCREVUS treatment compared with patients who started OCREVUS after the double-blind period Interim analysis of Phase IIIb study shows 87 percent of patients with suboptimal response to previous treatment had no evidence of disease activity one year after switching to OCREVUS Separ
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer
New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment Data will be submitted to health authorities around the world, inc
New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment Data will be submitted to health authorities around the world, inc
Pioneering data research centres to enable cutting-edge research and innovation to benefit UK patients
The University of Birmingham will play a key role in new data hubs that will enable cutting-edge research for health discoveries and aim to give patients across the UK faster access to pioneering new treatments. Led by Health Data Research UK , the hubs aim to improve the lives of people with debilitating conditions, and will link up different types of health data and make it more easily accessible and user-friendly for research, while maintaining strict controls around data privacy and consent.
The University of Birmingham will play a key role in new data hubs that will enable cutting-edge research for health discoveries and aim to give patients across the UK faster access to pioneering new treatments. Led by Health Data Research UK , the hubs aim to improve the lives of people with debilitating conditions, and will link up different types of health data and make it more easily accessible and user-friendly for research, while maintaining strict controls around data privacy and consent.
Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum
Roche's satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum Pivotal phase III SAkuraStar study shows 55% reduction in the risk of rela
Roche's satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum Pivotal phase III SAkuraStar study shows 55% reduction in the risk of rela
Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy
Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)Bullet Roche today announced positive data from the Phase
Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)Bullet Roche today announced positive data from the Phase
FDA Phase 1 Trial Shows Hydrogel to Repair Heart Is Safe to Inject in Humans-A First
Ventrix, a University of California San Diego spin-off company, has successfully conducted a first-in-human, FDA-approved Phase 1 clinical trial of an injectable hydrogel that aims to repair damage and restore cardiac function in heart failure patients who previously suffered a heart attack. The trial is the first to test a hydrogel designed to repair cardiac tissue.
Ventrix, a University of California San Diego spin-off company, has successfully conducted a first-in-human, FDA-approved Phase 1 clinical trial of an injectable hydrogel that aims to repair damage and restore cardiac function in heart failure patients who previously suffered a heart attack. The trial is the first to test a hydrogel designed to repair cardiac tissue.
The U.S. Food and Drug Administration has approved a new antibiotic that, in combination with two existing antibiotics, can tackle one of the most formidable and deadly treatment-resistant forms of the bacterium that causes tuberculosis .
Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS
Blood neurofilament light chain (NfL) levels were significantly lowered following OCREVUS treatment in analyses of Phase III studies in RMS and PPMS New data show NfL may be a biomarker for predicting future disability outcomes Separate analyses presented from one of the first studies to demonstrate NfL levels are correlated with active MRI lesions in PPMS Roche today announced new data from OCREVUS (ocrelizumab) trials in relapsing and primary progressive multiple sclerosis (MS).
Blood neurofilament light chain (NfL) levels were significantly lowered following OCREVUS treatment in analyses of Phase III studies in RMS and PPMS New data show NfL may be a biomarker for predicting future disability outcomes Separate analyses presented from one of the first studies to demonstrate NfL levels are correlated with active MRI lesions in PPMS Roche today announced new data from OCREVUS (ocrelizumab) trials in relapsing and primary progressive multiple sclerosis (MS).
Novartis data confirm long-term efficacy and safety of Aimovig for majority of patients with episodic migraine
The 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years
The 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years
Validates guidelines on treating patients with an underactive thyroid
A study led by the University of Birmingham provides strong support for current recommendations on treating patients with an underactive thyroid and validates latest UK and US guidelines, say researchers. The retrospective cohort study , published in The BMJ , analysed anonymous GP records of over 162,000 patients who have been diagnosed with hypothyroidism - a highly prevalent condition more commonly known as an underactive thyroid.
A study led by the University of Birmingham provides strong support for current recommendations on treating patients with an underactive thyroid and validates latest UK and US guidelines, say researchers. The retrospective cohort study , published in The BMJ , analysed anonymous GP records of over 162,000 patients who have been diagnosed with hypothyroidism - a highly prevalent condition more commonly known as an underactive thyroid.
European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stag
Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stag
Pharmacology - 13:01
Novartis receives positive CHMP opinion for Mayzent (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)
Novartis receives positive CHMP opinion for Mayzent (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)
Art - Nov 13
Midlands Art Papers launches special issue on inclusion, disability and access in the arts
Midlands Art Papers launches special issue on inclusion, disability and access in the arts
Pharmacology - Nov 12
New Novartis PREVENT data show Cosentyx delivers early relief in axial spondyloarthritis
New Novartis PREVENT data show Cosentyx delivers early relief in axial spondyloarthritis
Health - Nov 12
Sandoz presents real-world data showing effectiveness of Erelzi (etanercept-szzs) in rheumatic disease treatment
Sandoz presents real-world data showing effectiveness of Erelzi (etanercept-szzs) in rheumatic disease treatment
Life Sciences - Nov 12
Stanford opens ’team science’ complex for brain research and molecular discovery
Stanford opens ’team science’ complex for brain research and molecular discovery